Longitudinal Changes in Patient-reported Dyspnea in Patients with COPD

被引:24
作者
Mahler, Donald A. [1 ,2 ]
Ward, Joseph [1 ]
Waterman, Laurie A. [1 ]
Baird, John C. [3 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Sect Pulm & Crit Care Med, Pulm Funct & Cardiopulm Exercise Labs, Lebanon, NH 03756 USA
[2] Geisel Sch Med Dartmouth, Sect Pulm & Crit Care Med, Hanover, NH USA
[3] Psychol Applicat LLC, S Pomfret, VT USA
基金
美国国家卫生研究院;
关键词
Monitoring symptoms; Impact of daily activities on dyspnea; Transition dyspnea index; Modified Medical Research Council scale; University of California San Diego shortness-of- breath questionnaire; OBSTRUCTIVE PULMONARY-DISEASE; AMERICAN THORACIC SOCIETY; FLUTICASONE PROPIONATE; LUNG-FUNCTION; MANAGEMENT; REHABILITATION; TIOTROPIUM; EFFICACY; OUTCOMES; SALMETEROL;
D O I
10.3109/15412555.2012.701678
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Although guidelines recommend monitoring symptoms in patients with chronic obstructive pulmonary disease (COPD), there is limited information on the longitudinal changes in patient-reported dyspnea (PRD) related to activities of daily living. The hypothesis was that PRD scores on the modified Medical Research Council (mMRC) scale, the self-administered computerized (SAC) transition dyspnea index (TDI), and the University of California San Diego Shortness of Breath questionnaire (UCSD SOBQ) would demonstrate progression over two years. Methods: Observational cohort study of symptomatic patients with stable COPD evaluated every 6 months for 2 years. Patients rated the impact of activities of daily living on dyspnea using three patient-reported instruments presented in random order, and then performed post-bronchodilator (pBD) spirometry. Results: Seventy patients (37 female/33 male; age: 66 +/- 9 years; and pBD forced expiratory volume in one second [(FEV1): 51 +/- 16 % predicted] participated. Using fixed effects regression modeling, there was significant worsening in the PRD scores with the SAC TDI (-0.9 +/- 2.7; p = 0.03) and UCSD SOBQ (+5.7 +/- 18.3; p = 0.001), but not with the mMRC scale (p = 0.52). Both pBD FEV1 (p = 0.19) and pBD forced vital capacity (p = 0.65) were unchanged. Conclusions: Multidimensional instruments (SAC TDI and UCSD SOBQ) demonstrated the frequently observed decline in PRD experienced by patients with COPD. The progression in PRD occurred despite stable lung function. Monitoring PRD provides unique clinical information and should be considered along with measuring lung function to assess patient status over time.
引用
收藏
页码:522 / 527
页数:6
相关论文
共 47 条
  • [1] [Anonymous], 2011, GLOB STRAT DIAGN MAN
  • [2] Pulmonary biomarkers in chronic obstructive pulmonary disease
    Barnes, Peter J.
    Chowdhury, Badrul
    Kharitonov, Sergei A.
    Magnussen, Helgo
    Page, Clive P.
    Postma, Dirkje
    Saetta, Marina
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (01) : 6 - 14
  • [3] Brooks SM., 1982, ATS NEWS, V8, P12
  • [4] California Pulmonary Rehabilitation Collaborative Group, 2004, J Cardiopulm Rehabil, V24, P52
  • [5] Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Calverley, Peter M. A.
    Anderson, Julie A.
    Celli, Bartolome
    Ferguson, Gary T.
    Jenkins, Christine
    Jones, Paul W.
    Yates, Julie C.
    Vestbo, Jorgen
    Calverley, P. M. A.
    Anderson, J. A.
    Celli, B.
    Ferguson, G. T.
    Jenkins, C.
    Jones, P. W.
    Knobil, K.
    Yates, J. C.
    Vestbo, J.
    Cherniack, R.
    Similowski, T.
    Cleland, J.
    Whitehead, A.
    Wise, R.
    McGarvey, L.
    John, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) : 775 - 789
  • [6] Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
    Calverley, PM
    Boonsawat, W
    Cseke, Z
    Zhong, N
    Peterson, S
    Olsson, H
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) : 912 - 919
  • [7] A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
    Casaburi, R
    Mahler, DA
    Jones, PW
    Wanner, A
    San Pedro, G
    ZuWallack, RL
    Menjoge, SS
    Serby, CW
    Witek, T
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) : 217 - 224
  • [8] The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous The Experience of the BODE Cohort
    Casanova, Ciro
    de Torres, Juan P.
    Aguirre-Jaime, Armando
    Pinto-Plata, Victor
    Marin, Jose M.
    Cordoba, Elizabeth
    Baz, Rebeca
    Cote, Claudia
    Celli, Bartolome R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (09) : 1015 - 1021
  • [9] Outcomes for COPD pharmacological trials:: from lung function to biomarkers
    Cazzola, M.
    MacNee, W.
    Martinez, F. J.
    Rabe, K. F.
    Franciosi, L. G.
    Barnes, P. J.
    Brusasco, V.
    Burge, P. S.
    Calverley, P. M. A.
    Celli, B. R.
    Jones, P. W.
    Mahler, D. A.
    Make, B.
    Miravitlles, M.
    Page, C. P.
    Palange, P.
    Parr, D.
    Pistolesi, M.
    Rennard, S. I.
    Moelken, M. P. Rutten-Van
    Stockley, R.
    Sullivan, S. D.
    Wedzicha, J. A.
    Wouters, E. F.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (02) : 416 - 468
  • [10] Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study
    Celli, Bartolome R.
    Thomas, Nicola E.
    Anderson, Julie A.
    Ferguson, Gary T.
    Jenkins, Christine R.
    Jones, Paul W.
    Vestbo, Jorgen
    Knobil, Katharine
    Yates, Julie C.
    Calverley, Peter M. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (04) : 332 - 338